These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

212 related articles for article (PubMed ID: 26875907)

  • 1. Valsartan attenuates cardiac and renal hypertrophy in rats with experimental cardiorenal syndrome possibly through down-regulating galectin-3 signaling.
    Zhang MJ; Gu Y; Wang H; Zhu PF; Liu XY; Wu J
    Eur Rev Med Pharmacol Sci; 2016; 20(2):345-54. PubMed ID: 26875907
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Aggravated Cardiac Remodeling post Aortocaval Fistula in Unilateral Nephrectomized Rats.
    Wu J; Cheng Z; Gu Y; Zou W; Zhang M; Zhu P; Hu S
    PLoS One; 2015; 10(8):e0134579. PubMed ID: 26252578
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Apocynin Attenuates Cardiac Injury in Type 4 Cardiorenal Syndrome via Suppressing Cardiac Fibroblast Growth Factor-2 With Oxidative Stress Inhibition.
    Liu Y; Liu Y; Liu X; Chen J; Zhang K; Huang F; Wang JF; Tang W; Huang H
    J Am Heart Assoc; 2015 Jun; 4(7):. PubMed ID: 26109504
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Higenamine Improves Cardiac and Renal Fibrosis in Rats With Cardiorenal Syndrome via ASK1 Signaling Pathway.
    Deng T; Wei Z; Gael A; Deng X; Liu Y; Lai J; Hang L; Yan Q; Fu Q; Li Z
    J Cardiovasc Pharmacol; 2020 Jun; 75(6):535-544. PubMed ID: 32168151
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Kidney Response to Heart Failure: Proteomic Analysis of Cardiorenal Syndrome.
    Melenovsky V; Cervenka L; Viklicky O; Franekova J; Havlenova T; Behounek M; Chmel M; Petrak J
    Kidney Blood Press Res; 2018; 43(5):1437-1450. PubMed ID: 30235455
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Subtotal nephrectomy accelerates pathological cardiac remodeling post-myocardial infarction: implications for cardiorenal syndrome.
    Liu S; Kompa AR; Kumfu S; Nishijima F; Kelly DJ; Krum H; Wang BH
    Int J Cardiol; 2013 Oct; 168(3):1866-80. PubMed ID: 23347614
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Combined levosimendan and Sacubitril/Valsartan markedly protected the heart and kidney against cardiorenal syndrome in rat.
    Sung PH; Chai HT; Yang CC; Chiang JY; Chen CH; Chen YL; Yip HK
    Biomed Pharmacother; 2022 Apr; 148():112745. PubMed ID: 35202913
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Carvedilol prevents cardiac hypertrophy and overexpression of hypoxia-inducible factor-1alpha and vascular endothelial growth factor in pressure-overloaded rat heart.
    Shyu KG; Liou JY; Wang BW; Fang WJ; Chang H
    J Biomed Sci; 2005; 12(2):409-20. PubMed ID: 15942707
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Qiliqiangxin Protects against Renal Injury in Rat with Cardiorenal Syndrome Type I through Regulating the Inflammatory and Oxidative Stress Signaling.
    Duan X; Yan F; Hu H; Liu H; Wu Q; Sun S; Ming X; Bu X; He Y; Zhu H
    Biol Pharm Bull; 2018; 41(8):1178-1185. PubMed ID: 30068867
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Dyrk1A-ASF-CaMKIIδ Signaling Is Involved in Valsartan Inhibition of Cardiac Hypertrophy in Renovascular Hypertensive Rats.
    Yao J; Qin X; Zhu J; Sheng H
    Cardiology; 2016; 133(3):198-204. PubMed ID: 26619200
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Inhibition of apoptosis signal-regulating kinase 1 ameliorates left ventricular dysfunction by reducing hypertrophy and fibrosis in a rat model of cardiorenal syndrome.
    Savira F; Wang BH; Edgley AJ; Jucker BM; Willette RN; Krum H; Kelly DJ; Kompa AR
    Int J Cardiol; 2020 Jul; 310():128-136. PubMed ID: 32305147
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Renal protective effects and mechanisms of the angiotensin receptor-neprilysin inhibitor LCZ696 in mice with cardiorenal syndrome.
    Li Y; Kang L; Rong K; Zhang Y; Suo Y; Yuan M; Bao Q; Shao S; Tse G; Li R; Liu T; Li G
    Life Sci; 2021 Sep; 280():119692. PubMed ID: 34102189
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Impact of aortocaval shunt flow on cardiac and renal function in unilateral nephrectomized rats.
    Wu J; Cheng Z; Zhang M; Zhu P; Gu Y
    Sci Rep; 2016 Jun; 6():27493. PubMed ID: 27279232
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Establishment of rat model of cardiorenal syndrome by transabdominal subtotal nephrectomy].
    Cao H; Ji TW; Lan Q; Lin F; Dong Y; Xu AJ; Liu J; Ding HY; Fan HM; Liu ZM
    Zhonghua Yi Xue Za Zhi; 2019 Feb; 99(6):447-452. PubMed ID: 30786340
    [No Abstract]   [Full Text] [Related]  

  • 15. [Effects of valsartan, mycophenolate mofetil and their combined application on TRAIL and nuclear factor-kappaB expression in the kidneys of diabetic rats].
    Chen B; Zhang Y; Liu G; Guan GJ; Hou XH; Li XG; Liu JL
    Zhonghua Yi Xue Za Zhi; 2008 Feb; 88(8):540-5. PubMed ID: 18649770
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The impact of galectin-3 inhibition on aldosterone-induced cardiac and renal injuries.
    Calvier L; Martinez-Martinez E; Miana M; Cachofeiro V; Rousseau E; Sádaba JR; Zannad F; Rossignol P; López-Andrés N
    JACC Heart Fail; 2015 Jan; 3(1):59-67. PubMed ID: 25458174
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Protective effects of naringenin in cardiorenal syndrome.
    Liu Y; An W; Gao A
    J Surg Res; 2016 Jun; 203(2):416-23. PubMed ID: 27363651
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Heme arginate therapy enhanced adiponectin and atrial natriuretic peptide, but abated endothelin-1 with attenuation of kidney histopathological lesions in mineralocorticoid-induced hypertension.
    Ndisang JF; Jadhav A
    J Pharmacol Exp Ther; 2010 Jul; 334(1):87-98. PubMed ID: 20392817
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Protective effects of valsartan and benazepril combined with atorvastatin on cardiorenal syndrome in rats.
    Tang SY; Peng DF; Hu YJ; Chen J
    Eur Rev Med Pharmacol Sci; 2015; 19(5):759-66. PubMed ID: 25807427
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Chronic kidney disease with comorbid cardiac dysfunction exacerbates cardiac and renal damage.
    Liu S; Wang BH; Kelly DJ; Krum H; Kompa AR
    J Cell Mol Med; 2018 Jan; 22(1):628-645. PubMed ID: 28994186
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.